Apriligen
1 known investors
Apriligen develops autologous gene therapies for pediatric monogenic diseases, starting with Diamond Blackfan Anemia Syndrome. The company uses lentiviral technology to correct genetic defects by modifying patients' own cells, aiming to provide curative alternatives to traditional transplants.
BiotechHealthtechMedical Devices
Investors · 1
In the news
- Apriligen, Inc. - Connecticut Innovations Connecticut Innovationsctinnovations.com · 2024
- Online Platform for SAMD9 and SAMD9L Variant Annotation and Phenotype Correlation | Blood | American Society of Hematologyashpublications.org · 2022
- Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial | Blood | American Society of Hematologyashpublications.org · 2022